source
- Lilly’s $3.8B psychedelics bet won’t open the M&A floodgatesEli Lilly’s $3.8 billion play for AtaiBeckley has fueled speculation that Big Pharma is ready to embrace psychedelics. But while the acquisition does validate the drug class, analysts say it is unl…
- Sanofi halts development of Kymab-derived OX40L antibody for atopic dermatitisSanofi announced that it will no longer pursue the OX40L antibody program it was developing with Kymab for the treatment of atopic dermatitis. The drug was being positioned as a potential follow‑on…